Product Images Pemetrexed

This appears to be a graph showing the overall survival percentage (%) for a certain treatment arm over a period of 21 months. The treatment arm seems to be using a combination of Pemetrexed for Injection, pembrolizumab, and platinum chemotherapy (PI+P+C) compared to Pemetrexed for Injection and placebo with platinum chemotherapy (PI+C). The numbers at risk are also shown.*

This appears to be a table showing survival probability using different treatments for patients. The treatments mentioned are Pomatrexad with Injection and Cisplatin, as well as Gemcitabine with Cisplatin. The table also lists the number of patients at risk for each treatment and the corresponding survival times in months. However, the table is not clear and some of the characters are unreadable or misaligned. Therefore, the data is not entirely reliable and may not be useful without further clarification.*

This appears to be a table showing survival time in months for two different treatments, Pemetraxad for Injection + Cisplatin (PIC) and Gemcitabine + Cisplatin (GC), along with the number of patients at risk for each treatment. The table also includes headings for "Patients at Risk" and "Survival Time (months)."*

This appears to be a table containing data on survival probability, Pometrexed for Injection, and a placebo. It includes information on the number of patients at risk, survival time in months, and some numerical values. The table appears to be incomplete and difficult to interpret without proper context, so a more specific description cannot be given.*

The provided text seems to be a table for predicting the risk of a patient. The table shows the probability of survival time in months for patients who are at risk. It includes data for placebo and 325 patients with different survival times from 2 to 82 months. The text does not provide any further context or information regarding the purpose of this table or how it was obtained.*

The text represents a table containing data on patients at risk. The first column shows the number of patients in two groups, Pl 116 and Placebo 66. The second column indicates the survival time in months. The other numbers in the table are not defined and may represent additional data or statistics.*

This is a medical chart depicting the survival probability and time of patients who were treated with Pomotroxed injection (Pl). It lists the probability of survival at different time intervals in percentages and the number of patients who survived at different periods in months. There are also some figures and text that seem to be missing or cut-off, making it difficult to interpret the data comprehensively.*

This appears to be a chart or graph related to a study on the survival probability of patients who were treated with a combination of Pemetrexed for Injection (PI) and Cisplatin versus those who were only treated with Cisplatin. The x-axis represents survival time in months and the y-axis represents the probability of survival. The chart shows the number of patients at risk for each treatment group at each time interval.*

This is a pharmaceutical product called Pemetrexed, which is only for intravenous use that comes in a single-dose vial with NDC number 0338-0720-01. The drug contains pemetrexed disodium equivalent to 100 mg of pemetrexed along with other chemicals in the vial. The drug is a cytotoxic agent, so the unused portion should be disposed of properly. The storage temperature required for this drug is 25°C. Baxter Healthcare Corporation, Deerfeld, IL manufactures and distributes it in the USA, and the product is made in Germany. The text contains some errors.*

This is a description of the drug Pemetrexed, which is intended for intravenous use only. The drug comes in a vial with 100 mg per vial. It is a cytotoxic agent and caution should be taken when handling. However, the text is not clear and parts of the text are incomplete or unclear.*

This is a cautionary label for Singo-DoseVial, a cytotoxic agent containing pemetrexed disodium for injection, intended for intravenous use. Each vial contains 500mg of pemetrexed with additives like hydrochloric acid or sodium hydroxide to adjust pH. The powder should be stored at 25°C, with permitted excursions to 15-30°C, and applied using controlled room temperature. The label warns to discard any unused portion of the drug. The manufacturer is Baxter Healthcare Corporation, located in Deerfield, IL, USA.*